Seroatlas · Human Serome Atlas

MYL12A

Myosin regulatory light chain 12A

Also known as: ML12A_HUMAN, MLCB, MRCL3, MRLC3, MYL2B

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: P19105
Gene: MYL12A
Ensembl: ENSG00000101608
Chromosome: 18
Canonical length: 171 aa
Protein class: Predicted intracellular proteins

OverviewNCBI Gene

This gene encodes a nonsarcomeric myosin regulatory light chain. This protein is activated by phosphorylation and regulates smooth muscle and non-muscle cell contraction. This protein may also be involved in DNA damage repair by sequestering the transcriptional regulator apoptosis-antagonizing transcription factor (AATF)/Che-1 which functions as a repressor of p53-driven apoptosis. Alternate splicing results in multiple transcript variants. A pseudogene of this gene is found on chromosome 8.[provided by RefSeq, Dec 2014]

Canonical amino-acid sequenceUniProt

171 residues, UniProt reviewed canonical sequence.

>P19105|MYL12A
     1  MSSKRTKTKT KKRPQRATSN VFAMFDQSQI QEFKEAFNMI DQNRDGFIDK EDLHDMLASL
    61  GKNPTDEYLD AMMNEAPGPI NFTMFLTMFG EKLNGTDPED VIRNAFACFD EEATGTIQED
   121  YLRELLTTMG DRFTDEEVDE LYREAPIDKK GNFNYIEFTR ILKHGAKDKD D

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against MYL12A can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Intracellular
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.41
Highest tissue expression: 3,965 nTPM

Expression across tissuesHPA

Tissue

heart muscle: 3,965 nTPM
skeletal muscle: 3,054 nTPM
tongue: 1,944 nTPM
blood vessel: 658 nTPM
tonsil: 563 nTPM
lung: 559 nTPM

Single-cell type

esophageal apical cells: 5,197 nCPM
platelets: 4,562 nCPM
megakaryocytes: 3,660 nCPM
extravillous trophoblasts: 1,632 nCPM
neutrophils: 1,589 nCPM
alveolar cells type 1: 1,157 nCPM

Immune cell

total PBMC: 4,519 nTPM
basophil: 3,175 nTPM
plasmacytoid DC: 2,493 nTPM
eosinophil: 2,389 nTPM
memory CD8 T-cell: 2,315 nTPM
gdT-cell: 2,293 nTPM

Brain region

choroid plexus: 102 nTPM
medulla oblongata: 77 nTPM
hypothalamus: 68 nTPM
spinal cord: 67 nTPM
white matter: 64 nTPM
thalamus: 62 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.76
gnomAD pLI: 0
gnomAD missense Z: 1.48
DepMap mean gene effect: -0.08
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 6% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

platelet aggregation

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of MYL12A in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads MYL12A as an antibody target. Whether an autoantibody or antibody against MYL12A could matter depends on whether native MYL12A is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

MYL12A is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label MYL12A as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...